In the present article, the need for a registry like this is justified as it is based on the current scenario of the treatment of end-stage heart failure, characterised by the progression of mechanical circulatory support and the limited availability of heart transplantation.
In addition, the availability of heart muscle biopsies from DMD patients is very limited, which prevents the mechanistic study and drug testing using native DMD patient heart cells and tissues.
Current treatments for heart failure are inadequate and the availability of hearts for transplantation is extremely limited.
One of the obstacles to a better understanding of the pathogenesis of human cardiomyopathies has been poor availability of heart-tissue samples at early stages of disease development.
The respective roles of increased circulating lipid substrates availability and of heart ability to take up fatty acid could be different in 14 and 21 weeks old ZDF rats, when overt diabetes is present, from their role in 7-weeks ZDF rats.
In silence we can concentrate, spend time in the availability of our heart, and be in reservoirs of light.
Due to the limited availability of patient heart tissue, we also interrogated gene expression changes from LMNA E161K mutant fibroblasts compared to a control fibroblast line from a LMNA normal individual.
So far, the only definitive treatment for heart failure is heart transplantation, which is precluded from wider application due to the limited availability of donor hearts and complications from immunosuppressive therapies [ 3].
Heart transplantation may be an effective treatment for end-stage heart failure; the applicability of this procedure, however, is seriously limited by the availability of donor hearts and the concurrent immunorejection upon transplantation [ 14, 15].
Given the limited availability of donor hearts, ventricular assist device (VAD) therapy is fast becoming an accepted alternative treatment strategy to treat end-stage heart failure.
However, cardiac transplant is still limited by the availability of donor hearts, and, while antirejection strategies have been generally effective, they may cause complications, such as accelerated atherosclerosis and changes in cardiac cells, that ultimately result in transplant failure.
